aTyr Pharma (ATYR) announced the appointment of Dalia Rayes as Head of Commercial, Global Efzofitimod Franchise. She will serve as a member of the Company’s executive leadership team, overseeing global commercial strategy and operations for the efzofitimod program in interstitial lung disease, including its lead indication in pulmonary sarcoidosis. Rayes most recently served as Senior Vice President, Head of Commercial for ChemoCentryx.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- aTyr Pharma director buys $15K in common stock
- aTyr Pharma (ATYR) Stock Soars 24% on Promising Drug Developments
- Buy Rating Affirmed for aTyr Pharma Amid Strategic Trial Adjustments and Financial Stability
- aTyr Pharma’s Earnings Call Highlights Progress and Challenges
- Strategic Adjustments and Promising Developments Lead to Buy Rating for aTyr Pharma
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue